BACKGROUND: Young people are at high risk of HIV and developing appropriate prevention programmes requires an understanding of the risk factors for HIV in this age group. We investigated factors associated with HIV among participants aged 15-30 years in a 2007-8 cross-sectional survey nested within a community-randomised trial of the MEMA kwa Vijana intervention in 20 rural communities in northwest Tanzania. METHODS: We analysed data for 7259(53%) males and 6476(47%) females. Using a proximate-determinant conceptual framework and conditional logistic regression, we obtained sex-specific Odds Ratios (ORs) for the association of HIV infection with socio-demographic, knowledge, behavioural and biological factors. RESULTS: HSV-2 infection was s...
Introduction: In Sub-Saharan Africa, over six million youth ages 15-24 are living with HIV. One prom...
OBJECTIVES: A randomized, double-blind, placebo-controlled trial (RCT) of herpes simplex virus type ...
Background: Testing and evaluating new HIV prevention products such as HIV vaccines, requires ident...
Young people are at high risk of HIV and developing appropriate prevention programmes requires an un...
To prepare for future HIV prevention trials, we conducted prospective cohort studies among women wor...
OBJECTIVES: To prepare for future HIV prevention trials, we conducted prospective cohort studies amo...
To prepare for future HIV prevention trials, we conducted prospective cohort studies among women wor...
<div><p>Objectives</p><p>To prepare for future HIV prevention trials, we conducted prospective cohor...
To prepare for future HIV prevention trials, we conducted prospective cohort studies among women wor...
BACKGROUND: HIV prevalence trends in Tanzania differ between socioeconomic groups. While HIV prevale...
INTRODUCTION: Risk reduction towards safer behaviour is promoted after enrolment in HIV prevention t...
OBJECTIVE: To describe the evolution of the HIV-1 epidemic among women attending antenatal clinics i...
OBJECTIVES: To determine prevalence of and risk factors for herpes simplex virus type 2 (HSV-2) and ...
Variability in stages of the HIV-1 epidemic and hence HIV-1 prevalence exists in different areas in ...
Introduction: In Sub-Saharan Africa, over six million youth ages 15-24 are living with HIV. One prom...
Introduction: In Sub-Saharan Africa, over six million youth ages 15-24 are living with HIV. One prom...
OBJECTIVES: A randomized, double-blind, placebo-controlled trial (RCT) of herpes simplex virus type ...
Background: Testing and evaluating new HIV prevention products such as HIV vaccines, requires ident...
Young people are at high risk of HIV and developing appropriate prevention programmes requires an un...
To prepare for future HIV prevention trials, we conducted prospective cohort studies among women wor...
OBJECTIVES: To prepare for future HIV prevention trials, we conducted prospective cohort studies amo...
To prepare for future HIV prevention trials, we conducted prospective cohort studies among women wor...
<div><p>Objectives</p><p>To prepare for future HIV prevention trials, we conducted prospective cohor...
To prepare for future HIV prevention trials, we conducted prospective cohort studies among women wor...
BACKGROUND: HIV prevalence trends in Tanzania differ between socioeconomic groups. While HIV prevale...
INTRODUCTION: Risk reduction towards safer behaviour is promoted after enrolment in HIV prevention t...
OBJECTIVE: To describe the evolution of the HIV-1 epidemic among women attending antenatal clinics i...
OBJECTIVES: To determine prevalence of and risk factors for herpes simplex virus type 2 (HSV-2) and ...
Variability in stages of the HIV-1 epidemic and hence HIV-1 prevalence exists in different areas in ...
Introduction: In Sub-Saharan Africa, over six million youth ages 15-24 are living with HIV. One prom...
Introduction: In Sub-Saharan Africa, over six million youth ages 15-24 are living with HIV. One prom...
OBJECTIVES: A randomized, double-blind, placebo-controlled trial (RCT) of herpes simplex virus type ...
Background: Testing and evaluating new HIV prevention products such as HIV vaccines, requires ident...